Annual Revenue Comparison: Amphastar Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.

Pharma Giants' Revenue Battle: Amphastar vs. Taro (2014-2023)

__timestampAmphastar Pharmaceuticals, Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 2014210461000759285000
Thursday, January 1, 2015251519000862944000
Friday, January 1, 2016255165000950751000
Sunday, January 1, 2017240175000879387000
Monday, January 1, 2018294666000661913000
Tuesday, January 1, 2019322357000669893000
Wednesday, January 1, 2020349846000644769000
Friday, January 1, 2021437768000548970000
Saturday, January 1, 2022498987000561347000
Sunday, January 1, 2023644395000572952000
Monday, January 1, 2024629182000
Loading chart...

Infusing magic into the data realm

A Tale of Two Pharmaceutical Giants: Revenue Trends from 2014 to 2023

In the competitive landscape of pharmaceuticals, Amphastar Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. have showcased intriguing revenue trajectories over the past decade. From 2014 to 2023, Amphastar's revenue surged by over 200%, peaking in 2023 with a remarkable 644 million USD. In contrast, Taro's revenue, while initially higher, experienced a gradual decline, dropping by approximately 24% from its 2016 peak of 951 million USD to 573 million USD in 2023.

This divergence highlights Amphastar's robust growth strategy, possibly driven by innovative product lines and strategic market expansions. Meanwhile, Taro's revenue fluctuations suggest challenges in maintaining its market dominance. The data for 2024 remains incomplete, leaving room for speculation on future trends. As these companies navigate the ever-evolving pharmaceutical industry, their financial performances offer valuable insights into their strategic directions and market adaptability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025